Queensland University (Australia), “at the cutting edge of research into bioprinting on an international scale” (Gènéthqiue press review on May 19th, 2014) has just announced its links with Organovo, an American company specialising in 3D technology to imprint human tissues.
The aim of this joint venture is to perfect the first 3D imprinted kidney before testing drug toxicity “under conditions close to reality”. This task has been given to Professor Melissa Little at Queensland University. She explained that, “If we can test a drug for kidney toxicity before commencing human trials, we’ll save a lot of time, effort and, of course, money”. She went on to say that the end objective was “obviously to imprint kidneys with a view to transplanting them to humans”.
Early in the year, Organovo announced that it had imprinted human liver cells (Gènéthique press review on February 10th, 2014).